1. Body JJ (2003) Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 97(Suppl): 859–865
2. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergström B (2003a) On behalf of the MF 4265 Study Group. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14: 1399–1405
3. Body JJ, Diel I, Tripathy D, Bergstrom B (2003b) Impact of ibandronate on bone pain in patients with metastatic bone disease from breast cancer. Support Care Cancer 11: 395–396 (abstract A-34)
4. Body JJ, Kanis J, Diel I, Bergstrom B (2003c) Risk reductions in metastatic breast cancer: multivariate Poisson regression analyses of oral and i.v. ibandronate. Proc ASCO 22: 46 (abstract 184)
5. Diel I, Bell R, Tripathy D, Body JJ, Bergström B (2003) Renal safety of oral and intravenous ibandronate in metastatic bone disease: phase III clinical trial results. Support Care Cancer 11: 415 (abstract A-106)